echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Libtayo improves the survival rate of cervical cancer patients!

    Libtayo improves the survival rate of cervical cancer patients!

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sanofi and Regeneron's PD-1 inhibitor Libtayo showed positive overall survival (OS) results in a phase III clinical trial for advanced cervical cancer.


    The trial recruited patients with advanced cervical cancer.


    In the overall population, the median survival time of patients receiving Libtayo was 12.


    Israel Lowy, senior vice president of tumor transformation and clinical sciences at Regeneron, said: "It is well known that recurrent or metastatic cervical cancer is difficult to treat after first-line chemotherapy and there is no approved standard of care.


     

    Original source:

    Original source:

    http:// href="http://" target="_blank" rel="noopener">http:// style="vertical-align: inherit;"> http:// in this message

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.